Validation of the 2018 Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) Guidelines for Preventing Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy

Key Points

• To validate the effectiveness of the 2018 JCS/JHFS guidelines for stratifying the risk of sudden cardiac death in hypertrophic cardiomyopathy patients.
• Validation of the 2018 JCS/JHFS guidelines
• Assessment of sudden cardiac death risk stratification
• Focus on Class 2a recommendation for implantable cardioverter defibrillator
• Guidelines exhibited good discriminatory performance for SCD risk stratification
• Particularly effective among patients categorized with Class 2a recommendations